Cimeio Therapeutics Therapy Platform Featured in Forbes Article

Basel, Switzerland, and Cambridge, MA, August 20, 2024

Cimeio Therapeutics is thrilled to announce that our therapy platform has been featured in a recent Forbes article, highlighting our groundbreaking work in blood cancer therapy. The Forbes article underscores the promise of our technology platform and discusses how our innovative shielded-cell and immunotherapy pairs have the potential to revolutionize the treatment of hematologic malignancies.

We’re very proud that our team’s hard work in developing and testing our platform, results of which we’re recently published in Nature (link to article), have been recognized by Forbes as one of the leading approaches in a push towards a universal blood cancer therapy. It is a testament to our commitment of advancing universal blood cancer therapies and addressing the limitations of current treatments.

About Cimeio

Cimeio is an immunotherapy company developing Shielded-Cell & Immunotherapy Pairs™ (SCIP), novel immunotherapies which have the potential to transform treatment of hematologic diseases. Cimeio develops immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in HSCs. These novel epitopes edited variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. Shielded Cell and Immunotherapy Pairs and SCIP are trademarks of Cimeio Therapeutics, Inc. For more information, please visit www.cimeio.com.

Contact:
Steve Edelson
sedelson@versantventures.com
415-801-8088